EUVIMEDEUVIMED entdecken
Open Access

Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial

Alexandra Power-Hays, Ruth Namazzi, Charles Kato, Kathryn E McElhinney, Andrea L Conroy, Heather Hume, Chandy John, Sara M O'Hara, Susan E Stuber, Adam Lane, Teresa S Latham, Robert O Opoka und 1 weitere

Acta Haematologica · 2024

DOI: 10.1159/000539541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Alexandra Power-Hays und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Antisickling Agents, Blood Transfusion, Hydroxyurea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FIC NIH HHS, NICHD NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

People with sickle cell anemia (SCA) may require frequent blood transfusions to treat acute and chronic complications. Hydroxyurea is a life-saving treatment for SCA that could also decrease the need for blood transfusions. Inadequate medication access and challenges in dose optimization limit the widespread use of hydroxyurea in Africa. If feasible, pharmacokinetic (PK) dosing might improve dose determination to minimize toxicities and maximize clinical benefits. The Alternative Dosing And Prevention of Transfusions (ADAPT, NCT05662098) trial will analyze the impact of hydroxyurea on transfusion rate and serve as a pilot study to evaluate the feasibility of PK-guided hydroxyurea dosing in Uganda.

Methods

Herein we describe the rationale and design of ADAPT, a prospective cohort study of ∼100 children with SCA in Jinja, Uganda. The primary hypothesis is that hydroxyurea will decrease blood transfusion use by ≥ 50%, comparing the transfusion incidence rate ratio between a 3-month pretreatment and a 12-month treatment period. A key secondary hypothesis is that our PK-dosing approach will generate a suitable hydroxyurea dose for ≥80% of participants. Every ADAPT participant will undergo hydroxyurea PK testing, and if a dose is generated within 15–35 mg/kg/day, participants will start on their individualized dose. If not, they will start on a default dose of 20 mg/kg/day. Hydroxyurea dose optimization will occur with periodic dose adjustments.

Conclusion

Overall, demonstrating the reduction in blood transfusion utilization with hydroxyurea treatment would provide leverage to increase hydroxyurea access, and PK-guided hydroxyurea dosing should optimize the safe and effective treatment of SCA across sub-Saharan Africa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellAntisickling AgentsBlood TransfusionHydroxyureaAdolescentChildChild, PreschoolFemaleHumansMalePilot ProjectsProspective StudiesUgandaClinical Trials, Phase I as Topic

Stichwörter der Autor:innen

HydroxyureaPersonalized medicinePharmacokineticsSickle cell anemiaTransfusion medicine

Substanzen

Antisickling AgentsHydroxyurea

Autor:innen und Institutionen

  • Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
  • Global Health Uganda, Kampala, Uganda.
  • Makerere University, Kampala, Uganda.
  • Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, Indiana, USA.
  • Division of Hematology/Oncology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Québec, Canada.

Förderung

  • FIC NIH HHS
  • NICHD NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Power-Hays, A., Namazzi, R., Kato, C., McElhinney, K. E., Conroy, A. L., Hume, H., John, C., O'Hara, S. M., Stuber, S. E., Lane, A., Latham, T. S., Opoka, R. O., & Ware, R. E. (2024). Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial. Acta Haematologica. https://doi.org/10.1159/000539541

Vancouver

Power-Hays A, Namazzi R, Kato C, McElhinney KE, Conroy AL, Hume H, et al. Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial. Acta Haematologica. 2024. doi:10.1159/000539541

BibTeX
@article{PowerHays2024,
  author = {Power-Hays, Alexandra and Namazzi, Ruth and Kato, Charles and McElhinney, Kathryn E and Conroy, Andrea L and Hume, Heather and John, Chandy and O'Hara, Sara M and Stuber, Susan E and Lane, Adam and Latham, Teresa S and Opoka, Robert O and Ware, Russell E},
  title = {Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000539541}
}
Kostenlos starten →